https://www.biospace.com/correcting-and-replacing-legochem-biosciences-announces-license-agreement-for-lcb84-trop2-targeted-adc
CORRECTING and REPLACING LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted...
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-09447
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive...
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable...
phase iii study
https://www.news-medical.net/news/20251030/TROP2-identified-as-a-promising-therapeutic-target-for-renal-medullary-carcinoma.aspx
TROP2 identified as a promising therapeutic target for renal medullary carcinoma
Oct 30, 2025 - Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with BostonGene, conducted the largest and most comprehensive molecular...
as atherapeutic targettrop2identifiedpromising
https://www.fiercebiotech.com/biotech/astrazeneca-outlines-ai-enabled-trop2-biomarker-strategy-daiichi-adc-after-limited-lung
AZ outlines AI-enabled TROP2 biomarker strategy for Daiichi ADC
Sep 8, 2024 - AstraZeneca is using the biomarker in the phase 3 AVANZAR trial, which is evaluating Dato-DXd in combination with Imfinzi and chemo in first-line NSCLC.
ai enabledazoutlinestrop2biomarker
https://www.prnewswire.com/news-releases/daiichi-sankyo-presents-preliminary-phase-1-data-for-trop2-targeting-adc-ds-1062-in-patients-with-non-small-cell-lung-cancer-at-2019-asco-annual-meeting-300860250.html
Daiichi Sankyo Presents Preliminary Phase 1 Data for TROP2 Targeting ADC DS-1062 in Patients with...
/PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that preliminary results from the dose escalation part of a phase 1...
https://www.spandidos-publications.com/10.3892/ijo.2018.4423/abstract
Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells
International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-09447&r=1
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive...
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable...
phase iii study